Ulrich Bierbach

List of Publications by Year in Descending Order

80 papers	2,398 citations	32 h-index	44 g-index
89 ext. papers	2,579 ext. citations	5.8 avg, IF	4.85 L-index

#	Paper	IF	Citations
80	Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma. *ChemMedChem*, **2021**, 16, 412-419	3.7	1
79	DNA Adduct Detection after Post-Labeling Technique with PCR Amplification (DNA-ADAPT-qPCR) Identifies the Pre-ribosomal RNA Gene as a Direct Target of Platinum-Acridine Anticancer Agents. *Chemistry - A European Journal*, **2021**, 27, 14681-14689	4.8	0
78	A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. *Scientific Reports*, **2020**, 10, 15201	4.9	3
77	Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity. *Angewandte Chemie*, **2020**, 132, 22149-22154	3.6	1
76	Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity. *Angewandte Chemie - International Edition*, **2020**, 59, 21965-21970	16.4	3
75	Effects of platinum-based anticancer drugs on the trace element profile of liver and kidney tissue from mice. *Journal of Trace Elements in Medicine and Biology*, **2019**, 54, 62-68	4.1	5
74	Effect of the nonleaving groups on the cellular uptake and cytotoxicity of platinum-acridine anticancer agents. *Inorganica Chimica Acta*, **2019**, 492, 150-155	2.7	4
73	Cysteine-Directed Bioconjugation of a Platinum(II)-Acridine Anticancer Agent. *Inorganic Chemistry*, **2019**, 58, 43-46	5.1	6
72	Platination of cysteine by an epidermal growth factor receptor kinase-targeted hybrid agent. *Chemical Communications*, **2018**, 54, 7479-7482	5.8	5
71	Large-Pore Functionalized Mesoporous Silica Nanoparticles as Drug Delivery Vector for a Highly Cytotoxic Hybrid Platinum-Acridine Anticancer Agent. *Chemistry - A European Journal*, **2017**, 23, 3386-3397	4.8	18
70	Human Serum Albumin-Delivered [Au(PEt)] Is a Potent Inhibitor of T Cell Proliferation. *ACS Medicinal Chemistry Letters*, **2017**, 8, 572-576	4.3	10
69	Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. *Chemical Science*, **2017**, 8, 2309-2314	9.4	62
68	Metal-Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics. *European Journal of Inorganic Chemistry*, **2017**, 2017, 1561-1572	2.3	14
67	Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. *Journal of Inorganic Biochemistry*, **2016**, 165, 170-180	4.2	12
66	Au-ACRAMTU-PEt3 Alters Redox Balance To Inhibit T Cell Proliferation and Function. *Journal of Immunology*, **2015**, 195, 1984-94	5.3	5
65	Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors. *Inorganic Chemistry*, **2015**, 54, 3316-24	5.1	19
64	Cellular Recognition and Repair of Monofunctional-Intercalative Platinum--DNA Adducts. *Chemical Research in Toxicology*, **2015**, 28, 2170-8	4	24

63	Target-selective delivery and activation of platinum-based anticancer agents. *Future Medicinal Chemistry*, **2015**, 7, 911-27	4.1	12
62	Investigating the cellular fate of a DNA-targeted platinum-based anticancer agent by orthogonal double-click chemistry. *Journal of Biological Inorganic Chemistry*, **2014**, 19, 415-26	3.7	23
61	Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent. *Chemistry - A European Journal*, **2014**, 20, 16164-73	4.8	20
60	Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study. *Chemistry - A European Journal*, **2014**, 20, 16174-87	4.8	33
59	PT-ACRAMTU, a platinum-acridine anticancer agent, lengthens and aggregates, but does not stiffen or soften DNA. *Cell Biochemistry and Biophysics*, **2013**, 67, 1103-13	3.2	13
58	The cell's nucleolus: an emerging target for chemotherapeutic intervention. *ChemMedChem*, **2013**, 8, 1441-9	3.7	41
57	Using Fluorescent Post-Labeling To Probe the Subcellular Localization of DNA-Targeted Platinum Anticancer Agents. *Angewandte Chemie*, **2013**, 125, 3434-3438	3.6	23
56	Using fluorescent post-labeling to probe the subcellular localization of DNA-targeted platinum anticancer agents. *Angewandte Chemie - International Edition*, **2013**, 52, 3350-4	16.4	62
55	Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer. *Chemical Communications*, **2013**, 49, 2415-7	5.8	17
54	Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells. *Metallomics*, **2012**, 4, 645-52	4.5	26
53	Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents. *Journal of Medicinal Chemistry*, **2012**, 55, 10198-203	8.3	38
52	Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents. *ACS Chemical Biology*, **2012**, 7, 1892-901	4.9	34
51	Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. *Journal of Medicinal Chemistry*, **2012**, 55, 7817-27	8.3	36
50	DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers. *Chemistry - A European Journal*, **2012**, 18, 12926-34	4.8	65
49	Interactions of a platinum-modified perylene derivative with the human telomeric G-quadruplex. *Journal of Physical Chemistry B*, **2011**, 115, 13701-12	3.4	27
48	Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. *Molecular Pharmaceutics*, **2011**, 8, 1941-54	5.6	28
47	Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay. *Journal of Biological Inorganic Chemistry*, **2011**, 16, 373-80	3.7	23
46	Unusual Reactivity of a Potent Platinum-Acridine Hybrid Antitumor Agent. *ACS Medicinal Chemistry Letters*, **2011**, 2, 687-691	4.3	20

45	Inhibition of DNA Synthesis by a Platinum-Acridine Hybrid Agent Leads to Potent Cell Kill in Non-Small Cell Lung Cancer. *ACS Medicinal Chemistry Letters*, **2011**, 2, 870-874	4.3	37
44	Probing platinum-adenine-n3 adduct formation with DNA minor-groove binding agents. *Chemical Research in Toxicology*, **2010**, 23, 1148-50	4	10
43	Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3423-5	2.9	7
42	Gold(I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis. *Journal of Medicinal Chemistry*, **2009**, 52, 6519-22	8.3	39
41	Replacement of a thiourea-S with an amidine-NH donor group in a platinum-acridine antitumor compound reduces the metal's reactivity with cysteine sulfur. *Journal of Medicinal Chemistry*, **2009**, 52, 3424-7	8.3	41
40	Tuning the DNA conformational perturbations induced by cytotoxic platinum-acridine bisintercalators: effect of metal cis/trans isomerism and DNA threading groups. *Journal of Medicinal Chemistry*, **2008**, 51, 3069-72	8.3	18
39	A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer. *Journal of Medicinal Chemistry*, **2008**, 51, 7574-80	8.3	92
38	Effect of linkage geometry on biological activity in thiourea- and guanidine-substituted acridines and platinum-acridines. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3799-801	2.9	17
37	Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity. *Journal of Medicinal Chemistry*, **2007**, 50, 2259-63	8.3	42
36	Unexpected Assembly of a Novel Triply Bridged Diiron(II) Core by a Bidentate Schiff Base Ligand. *Inorganica Chimica Acta*, **2007**, 360, 2824-2828	2.7	5
35	Kinetically favored platination of adenine in the g-rich human telomeric repeat. *Journal of the American Chemical Society*, **2007**, 129, 15764-5	16.4	36
34	Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores. *Anti-Cancer Agents in Medicinal Chemistry*, **2007**, 7, 125-38	2.2	32
33	Unexpected reactivity of the 9-aminoacridine chromophore in guanidylation reactions. *Journal of Organic Chemistry*, **2007**, 72, 5387-90	4.2	11
32	Synthesis, biological activity, and DNA-damage profile of platinum-threading intercalator conjugates designed to target adenine. *Journal of Medicinal Chemistry*, **2006**, 49, 3204-14	8.3	37
31	Structure-Activity Relationships Within Di- and Trinuclear Platinum Phase-I Clinical Anticancer Agents **2006**, 477-496		7
30	Guanine binding of a cytotoxic platinum-acridin-9-ylthiourea conjugate monitored by 1-D 1H and 2-D [1H,15N] NMR spectroscopy: hydrolysis is not the rate-determining step. *Journal of Inorganic Biochemistry*, **2006**, 100, 972-9	4.2	4
29	DNA minor groove adducts formed by a platinum-acridine conjugate inhibit association of tata-binding protein with its cognate sequence. *Biochemistry*, **2005**, 44, 11262-8	3.2	22
28	Duplex-promoted platination of adenine-N3 in the minor groove of DNA: challenging a longstanding bioinorganic paradigm. *Journal of the American Chemical Society*, **2005**, 127, 1160-9	16.4	44

27	Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent. *Biochemistry*, **2005**, 44, 6059-70	3.2	63
26	Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent. *Nucleic Acids Research*, **2005**, 33, 5622-32	20.1	32
25	Synthesis, structure, and reactivity of monofunctional platinum(II) and palladium(II) complexes containing the sterically hindered ligand 6-(methylpyridin-2-yl)acetate. *Journal of Inorganic Biochemistry*, **2005**, 99, 2013-23	4.2	15
24	A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 443-6	2.9	24
23	Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. *Cancer Chemotherapy and Pharmacology*, **2005**, 56, 337-43	3.5	24
22	Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. *Current Topics in Medicinal Chemistry*, **2004**, 4, 1537-49	3	90
21	Biophysical characterization and molecular modeling of the coordinative-intercalative DNA monoadduct of a platinum-acridinylthiourea agent in a site-specifically modified dodecamer. *Journal of Biological Inorganic Chemistry*, **2004**, 9, 335-44	3.7	22
20	Structure-activity relationships in platinum-acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxicity. *Journal of Biological Inorganic Chemistry*, **2004**, 9, 453-61	3.7	41
19	Unique base-step recognition by a platinum-acridinylthiourea conjugate leads to a DNA damage profile complementary to that of the anticancer drug cisplatin. *Biochemistry*, **2004**, 43, 8560-7	3.2	30
18	Metal-intercalator-mediated self-association and one-dimensional aggregation in the structure of the excised major DNA adduct of a platinum-acridine agent. *Journal of the American Chemical Society*, **2004**, 126, 4492-3	16.4	35
17	Bis(acridinylthiourea)platinum(II) complexes: synthesis, DNA affinity, and biological activity in glioblastoma cells. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 855-8	2.9	22
16	Unprecedented monofunctional metalation of adenine nucleobase in guanine- and thymine-containing dinucleotide sequences by a cytotoxic platinum-acridine hybrid agent. *Journal of the American Chemical Society*, **2003**, 125, 9629-37	16.4	47
15	Unusual intercalation of acridin-9-ylthiourea into the 5TGA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate. *Nucleic Acids Research*, **2003**, 31, 4138-46	20.1	37
14	Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. *Biochemical Pharmacology*, **2002**, 64, 191-200	6	73
13	Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2953-5	2.9	17
12	Thermally inert metal ammines as light-inducible DNA-targeted agents. Synthesis, photochemistry, and photobiology of a prototypical rhodium(III)-intercalator conjugate. *Inorganic Chemistry*, **2002**, 41, 7159-69	5.1	13
11	Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore. *Journal of Medicinal Chemistry*, **2001**, 44, 4492-6	8.3	116
10	Modulation of the chemical and biological properties of trans platinum complexes: monofunctional platinum complexes containing one nucleobase as potential antiviral chemotypes. *Journal of Biological Inorganic Chemistry*, **2000**, 5, 575-83	3.7	30

9	Inversion of the cis geometry requirement for cytotoxicity in structurally novel platinum(II) complexes containing the bidentate N,O-donor pyridin-2-yl-acetate. *Inorganic Chemistry*, **2000**, 39, 1882-90	5.1	41
8	Synthesis, Structure, Biological Activity, and DNA Binding of Platinum(II) Complexes of the Type trans-[PtCl(2)(NH(3))L] (L = Planar Nitrogen Base). Effect of L and Cis/Trans Isomerism on Sequence Specificity and Unwinding Properties Observed in Globally Platinated DNA. *Inorganic Chemistry*, **1999**, 38, 3535-3542	5.1	98
7	DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. *FEBS Journal*, **1998**, 254, 547-57		73
6	Structural and reactivity studies on the ternary system guanine/methionine/trans-[PtCl2(NH3)L] (L=NH3, quinoline): implications for the mechanism of action of nonclassical trans-platinum antitumor complexes. *Journal of Biological Inorganic Chemistry*, **1998**, 3, 570-580	3.7	23
5	Modification of Platinum(II) Antitumor Complexes with Sulfur Ligands. 2. Reactivity and Nucleotide Binding Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO3and [{PtCl(diamine)}2(L-L)](NO3)2(L = Monofunctional Thiourea Derivative; L-L = Bifunctional Thiourea Derivative) in Relation to Their Cytotoxicity. *Inorganic Chemistry*, **1998**, 37, 717-723	5.1	29
4	Modification of Platinum(II) Antitumor Complexes with Sulfur Ligands. 1. Synthesis, Structure, and Spectroscopic Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO3 and [{PtCl(diamine)}2(L-L)](NO3)2 (L = Monofunctional Thiourea Derivative; L-L = Bifunctional Thiourea Derivative). *Inorganic Chemistry*, **1998**, 37, 708-716	5.1	71
3	Modulation of Nucleotide Binding of trans Platinum(II) Complexes by Planar Ligands. A Combined Proton NMR and Molecular Mechanics Study. *Inorganic Chemistry*, **1997**, 36, 3657-3665	5.1	43
2	Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: Studies on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea Coordination. *Inorganic Chemistry*, **1996**, 35, 4865-4872	5.1	35
1	FeI3SC(NMe2)2, a Neutral Thiourea Complex of Iron(III) Iodide. *Angewandte Chemie International Edition in English*, **1989**, 28, 776-777		10